Igor Makhlin

Oncology
3400 Civic Center Boulevard
West Pavilion, 3rd Floor
Philadelphia, PA 19104

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications

Targeted Therapies, Sequencing Strategies, and Beyond in Metastatic Hormone Receptor-Positive Breast Cancer: ASCO Guideline Clinical Insights.

Targeted Therapies, Sequencing Strategies, and Beyond in Metastatic Hormone Receptor-Positive Breast Cancer: ASCO Guideline Clinical Insights.

Journal: JCO oncology practice
Published: August 27, 2024

Targeting dormant tumor cells to prevent recurrent breast cancer: a randomized phase 2 trial.

Targeting dormant tumor cells to prevent recurrent breast cancer: a randomized phase 2 trial.

Journal: Nature medicine
Published: June 29, 2024

Statins Do Not Significantly Affect Oxidative Nitrosative Stress Biomarkers in the PREVENT Randomized Clinical Trial.

Statins Do Not Significantly Affect Oxidative Nitrosative Stress Biomarkers in the PREVENT Randomized Clinical Trial.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: December 18, 2023

Adverse Cardiovascular Events Associated With Cyclin-Dependent Kinase 4/6 Inhibitors in Patients With Metastatic Breast Cancer.

Adverse Cardiovascular Events Associated With Cyclin-Dependent Kinase 4/6 Inhibitors in Patients With Metastatic Breast Cancer.

Journal: Journal of the American Heart Association
Published: June 10, 2023

Acute skin radiation toxicity seen with concurrent T-DM1: A single institutional report of 35 patients.

Acute skin radiation toxicity seen with concurrent T-DM1: A single institutional report of 35 patients.

Journal: Breast (Edinburgh, Scotland)
Published: October 28, 2022

18F-FDG PET/CT for the Evaluation of Therapy Response in Hormone Receptor-Positive Bone-Dominant Metastatic Breast Cancer.

18F-FDG PET/CT for the Evaluation of Therapy Response in Hormone Receptor-Positive Bone-Dominant Metastatic Breast Cancer.

Journal: Radiology. Imaging cancer
Published: October 21, 2022

Trastuzumab deruxtecan: An antibody-drug conjugate embracing its destiny in breast cancer.

Trastuzumab deruxtecan: An antibody-drug conjugate embracing its destiny in breast cancer.

Journal: Cell reports. Medicine
Published: June 22, 2022

Ruxolitinib and exemestane for estrogen receptor positive, aromatase inhibitor resistant advanced breast cancer.

Ruxolitinib and exemestane for estrogen receptor positive, aromatase inhibitor resistant advanced breast cancer.

Journal: NPJ breast cancer
Published: May 04, 2022

PAQR8 promotes breast cancer recurrence and confers resistance to multiple therapies.

PAQR8 promotes breast cancer recurrence and confers resistance to multiple therapies.

Journal: Breast cancer research : BCR
Published: April 23, 2022

Germline ERBB2/HER2 Coding Variants Are Associated with Increased Risk of Myeloproliferative Neoplasms.

Germline ERBB2/HER2 Coding Variants Are Associated with Increased Risk of Myeloproliferative Neoplasms.

Journal: Cancers
Published: May 19, 2021

Setting the Pick: Can PI3K Inhibitors Circumvent CDK4/6 Inhibitor Resistance?

Setting the Pick: Can PI3K Inhibitors Circumvent CDK4/6 Inhibitor Resistance?

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: October 05, 2020

On the Rise of Cyclin-Dependent Kinase Inhibitors in Breast Cancer: Progress & Ongoing Challenges.

On the Rise of Cyclin-Dependent Kinase Inhibitors in Breast Cancer: Progress & Ongoing Challenges.

Journal: Breast cancer management
Published: June 01, 2020
Showing 1-12 of 15

Last Updated: 09/26/2026